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Abstract
Background: It is not uncommon to observe circulating tumor antigen-specific T lymphocytes in
cancer patients despite a lack of significant infiltration and destruction of their tumors. Thus, an
important goal for tumor immunotherapy is to identify ways to modulate in vivo anti-tumor
immunity to achieve clinical efficacy. We investigate this proposition in a spontaneous mouse tumor
model, Rip1-Tag2.
Methods: Experimental therapies were carried out in two distinctive trial designs, intended to
either intervene in the explosive growth of small tumors, or regress bulky end-stage tumors. Rip1-
Tag2 mice received a single transfer of splenocytes from Tag-specific, CD4+ T cell receptor
transgenic mice, a single sub-lethal radiation, or a combination therapy in which the lymphocyte
transfer was preceded by the sub-lethal radiation. Tumor burden, the extent of lymphocyte
infiltration into solid tumors and host survival were used to assess the efficacy of these therapeutic
approaches.
Results: In either intervention or regression, the transfer of Tag-specific T cells alone did not
result in significant lymphocyte infiltration into solid tumors, not did it affect tumor growth or host
survival. In contrast, the combination therapy resulted in significant reduction in tumor burden,
increase in lymphocyte infiltration into solid tumors, and extension of survival.
Conclusions: The results indicate that certain types of solid tumors may be intrinsically resistant
to infiltration and destruction by tumor-specific T lymphocytes. Our data suggest that such
resistance can be disrupted by sub-lethal radiation. The combinatorial approach presented here
merits consideration in the design of clinical trials aimed to achieve T cell-mediated anti-tumor
immunity.
Background
With breakthroughs in molecular biology, basic immu-
nology and biotechnology, great progress has been made
in the field of tumor immunology. An increasing number
of tumor antigens have been identified [1]. Tumor vac-
cines have been successful in eliciting tumor-specific
CD4+ and/or CD8+ T cell responses. However, when T
cells reactive against tumor antigens are expanded ex vivo
and then transferred back into tumor-bearing hosts, re-
sults have been mixed in treating both melanoma [2–4]
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and lymphoma [5–7]. Several explanations for these vari-
able results have been suggested by studies of T cell immu-
nity in mice, involving experimental tumors derived from
inoculation of cell lines. In some circumstances, CD4+
and CD8+ T cells were rendered inactive in tumor-bearing
hosts [8]. The inactivation of CD4+ T cells has been attrib-
uted either to the tumor cells themselves or to bone mar-
row-derived cells [9–11], whereas antigen ignorance or
loss of memory have been postulated to underlay that of
CD8+ T cells [12,13]. Other studies have suggested that tu-
mor cells can secrete immunosuppressive factors such as
TGF-β  or express Fas ligand to induce apoptosis of infil-
trating lymphocytes [14–16]. Furthermore, the tumor vas-
culature appears to be quite different from normal blood
vessels, in terms of structural organization, interstitial
pressure, and flow patterns [17], and in reduced lym-
phocyte and natural killer cell homing and adhesion [18–
21]. The existence of significant barriers to effective im-
munological destruction is further illustrated by a mouse
model of concurrent multistage tumorigenesis and anti-
oncogene autoimmunity, wherein progenitor dysplastic
lesions are infiltrated and disrupted, while solid tumors
are not [22]. The hypothesis is that the microenvironment
of certain types of solid tumor can serve to locally sup-
press T cell infiltration. In such cases, one of the challeng-
es for tumor immunology is to find effective means to
overcome these barriers to productive efficacious anti-tu-
mor immunity.
Herein we sought to modulate anti-tumor immunity in a
transgenic mouse tumor model in which an oncogene,
SV40 large T antigen (Tag), is expressed in islet beta cells
under the control of the rat insulin promoter, Rip1 [23].
Several lines of Rip1-Tag mice have been generated and
characterized. Depending on the temporal and spatial or-
der of Tag expression, the Rip1-Tag mice are either immu-
nologically tolerant or responsive to Tag [24,25]. Mice in
the Rip1-Tag2 line begin to express Tag during embryo-
genesis. The mice show systemic tolerance to Tag, mount-
ing neither humoral nor cellular immune responses to Tag
upon immunization of purified protein [25,26]. Rip1-
Tag2 mice display a reproducible pattern of multistage tu-
mor development, from normal islets to hyperplastic/dys-
plastic islets, to angiogenic islets, to varying grades of solid
tumor, with a well-defined angiogenic progression [27].
All Rip1-Tag2 mice succumb to hypoglycemia and tumor
burden by 13–16 weeks. Mice with transgenes encoding T
cell receptors from H-2k-restricted CD4+ and CD8+ T cell
clones specific for Tag have been generated [28,29]. When
Rip1-Tag2 was crossed to TCR transgenic mice (TCR1) car-
rying Tag-specific CD4+ T cells, temporal induction of T
cell tolerance to Tag was detected in the pancreatic drain-
ing lymph nodes in the double transgenic mice [30]. The
T cell tolerance is manifested in reductions both of idio-
typic CD4+ T cell abundance and of the T cell proliferation
response to Tag in vitro.
Another line of Rip-Tag mice, Rip1-Tag5 has a different
spatial and temporal order of Tag expression [24]. Tag ex-
pression begins at approximately 10 weeks of age. Several
weeks later, a spontaneous autoimmune response to Tag
is readily detectable, with significant lymphocyte infiltra-
tion of hyperplastic/dysplastic islets. Mice in this line
readily mount a humoral and CTL response to Tag, and as
such are non-tolerant. Infiltration of premalignant lesions
is variable and occasionally intense, but is minimal in sol-
id tumors. Crosses of Rip1-Tag5 mice to transgenic mice
that either increased the abundance of anti-Tag CD4+ T
cells (TCR1) [28] or rendered the tumor cells co-stimula-
tory (Rip-B7-1) [31] dramatically enhanced the infiltra-
tion of premalignant lesions, but not of solid tumors [22].
Additionally, ex vivo stimulated Tag-specific CD4+ T cells
were transferred into Rip1-Tag5. Like many of the adop-
tive transfers of tumor-specific T cells in clinical cases [2–
7], no significant lymphocyte infiltration into solid tumor
was detected [22]. If, however, Rip1-Tag5 mice were treat-
ed with lethal radiation and subsequent reconstitution
with bone marrow from RAG1 deficient mice prior to T
cell transfer, modest lymphocyte infiltration into solid tu-
mors was noted [22]; however, this study did not assess
the efficacy of that response. Sub-lethal irradiation has
been successfully used to decrease tumor burden in com-
bination with a cytokine-producing tumor vaccine in a
murine renal cell carcinoma lung metastases model [32].
In the current study, we sought to achieve efficacious anti-
tumor immunity by disrupting the evident barriers pre-
sented by solid tumors in the Rip-Tag model. We chose
the Rip1-Tag2 line, for its phenotype of rapid, largely syn-
chronous tumorigenesis, and its systemic tolerance, rea-
soning that effects of experimental manipulations could
be readily distinguished. Lethal dose radiation followed
by bone marrow transplant can significantly impair the re-
sponsiveness of anti-tumor CD8+ T cells, dendritic cells,
eosinophiles and macrophages [8], and is a clinically un-
desirable therapeutic modality. Therefore, we hypothe-
sized that sub-lethal radiation might be more effective
and clinically acceptable in promoting anti-tumor immu-
nity. The results presented in this study suggest that sub-
lethal radiation is effective in augmenting adoptive anti-
tumor immunity in the Rip1-Tag2 model, underscoring
the potential value of perturbing the tumor microenviron-
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maintained on C3HeBFe background with 39–40 genera-
tions of backcross. Rip1-Tag2 mice have 100% incidence
of spontaneous insulinoma. Tag-TCR1 (referred to hereaf-
ter as TCR) transgenic mice expressing a T cell receptor
transgene with specificity to Tag were generated in the
B6D2F1 background and backcrossed to C3HeBFe for 20
generations [28]. About 10% of the splenic CD4+ T cells
in this transgenic line express the TCR transgene [28]. All
Rip1-Tag2 in all treatment groups received the same diet
throughout the experiment. All experimental procedures
were conducted in accordance with NIH and University of
California, San Francisco guidelines.
Intervention and regression trials
The Intervention trial was initiated when Rip1-Tag2 mice
reached the age of 10 weeks. Mice were sacrificed at 13
weeks of age for the determination of tumor burden. The
Regression Trial started at the age of 12.6 weeks (about 88
days after birth). The end point was at 16 weeks of age. In
both cases, cohorts of Rip1-Tag2 mice were set up for sur-
vival study. Mice were euthanized when they became
moribund.
Radiation of mice
Rip1-Tag2 mice at the specifically defined age were irradi-
ated in the Mark I model 68A cesium 137 irradiator (J. L.
Shepherd & Associates, San Fernando, CA). The dosage
used was 600R (6 Gy).
Adoptive transfer of cells
Splenocytes from TCR or non-transgenic C3H mice were
isolated. The cells were briefly hemolyzed, washed exten-
sively in DMEM containing 10% FBS, filtered through a
100 µM sterile nylon filter, counted by hemacytometer,
and suspended in complete medium. The cells were ad-
justed to a density of 1 ×  108 cells/ml and injected into the
intraperitoneal space of Rip1-Tag2 mice. Each mouse in
the treatment received 1 ml of splenocytes (1 ×  108 cells).
In the group that received both radiation and splenocyte
transfer, mice were irradiated at 600R one day prior to
splenocyte transfer.
Calculation of tumor burden
Rip1-Tag2 mice in each treatment were sacrificed at the
defined end points. Solid tumors were isolated, photo-
graphed, and measured. The tumor volume was calculated
using the following formula: volume = 0.52 ×  (width)2 ×
(length). Tumor burden per mouse was defined as the
sum of the volume of all macroscopic tumors. Intestinal
carcinoid tumors appear occasionally in Rip1-Tag2 mice.
Such tumors are associated with this particular line of Rip-
Tag transgenic mice (but not others) and were not the re-
sult of any of the treatments in the study. Thus, these ex-
tra-pancreatic tumors were recorded but not included in
the calculations in the current study.
Tissue preparation and immunohistochemistry
All histological analyses were done on frozen sections.
Samples were fresh frozen in Tissue-Tek O.C.T. com-
pound (Sakura Finetek, Torrance, CA USA) and sectioned
at 10 µM thickness. For immunohistochemistry, sections
were briefly fixed in cold acetone. They were then blocked
for 1 h in PBS with 5% normal goat serum. Slides were in-
cubated at room temperature for 1 h with the primary an-
tibodies. The samples were washed extensively in PBS and
then incubated with biotinylated secondary antibodies
(Vector Laboratories, Burlingame, CA). Endogenous per-
oxidase activity was quenched with 0.6% H2O2/methanol
for 4 minutes. Color on sections was developed with ABC-
horseradish peroxidase (Vector Laboratories) and 3,3'-di-
aminobenzidine substrate (Sigma, St. Louis, MO). H&E
staining was performed with hamatoxylin Gill #3 and
eosin Y (Sigma).
The following antibodies were used for immunohisto-
chemistry: anti-murine CD4 (H129.9); anti-murine CD8
(53-6.7); anti-murine CD11c (HL3); anti-murine CD31
(MEC 13.3) at recommended concentrations (PharMin-
gen, San Diego, CA).
Statistical analysis
Tumor burden was analyzed using the Mann-Whitney test
(InStat version 1.12, GraphPad Software). Survival data
was analyzed with a log-rank test (Prizm 3.0 A, GraphPad
software).
Results
Combinatorial efficacy of adoptive transfer and sub-lethal 
radiation
We used two distinctive therapeutic trial designs for the
treatment of tumors Rip1-Tag2 mice: intervention and re-
gression [33]. In each trial we used three experimental
arms as well as an untreated control group; the treatment
arms were adoptive transfer of tumor antigen specific T
cells, a sub-lethal dose of radiation (600R), or radiation
followed by adoptive transfer. In the intervention trial,
treatment occurred at a time when small, encapsulated ad-
enomas are forming (week 10 for Rip1-Tag2 mice). The
data are summarized in Figure 1. The mean tumor volume
at the start of the trial was 3 mm3. The average number of
tumors was 2.4. At the end of the study, the mean tumor
burden in the untreated control group was about 34 mm3
in volume and 7.6 in tumor number. Adoptive transfer of
splenocytes from TCR transgenic mice into Rip1-Tag2
mice produced a modest, but not statistically significant,
reduction in tumor volume (35%), and no change in tu-
mor number. Sub-lethal radiation alone significantly re-
duced tumor volume (53%, p = 0.03), but the mice had a
similar number of tumors (6.4). With the combination
treatment, a significant reduction in both tumor volume
(87%; p = 0.0004) and tumor number was observed. It isBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/11
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Figure 1
Intervention trial. Effect of treatment on (A) the mean tumor volume (mm3) +/- standard deviation and (B) mean tumor
number +/- standard deviation in 10 week old RIP1-Tag2 mice with small solid tumors for n = 8–11 mice. IT10w stands for ini-
tial tumor burden and tumor number. Statistical analysis was done using a two-tailed, unpaired Mann-Whitney test. P values
comparing experimental groups to untreated control mice are 0.03 [1], 0.0004 [2], and 0.0044 [4], respectively. P value com-
paring 600R treated mice to TCR+600R is 0.0055 [3].BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/11
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Figure 2
Regression Trial. Effect of treatment on (A) the mean tumor volume (mm3) +/- standard deviation and (B) mean tumor
number +/- standard deviation in 13 week old RIP1-Tag2 mice with large solid tumors for n = 8–11 mice. IT13w stands for ini-
tial tumor burden and tumor number. Statistical analysis was done using a two-tailed, unpaired Mann-Whitney test. P values
comparing experimental groups to untreated control mice are 0.0149 [1] and 0.0009 [2], respectively. P value comparing 600R
treated mice to TCR+600R is 0.0006 [3].BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/11
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Figure 3
Adoptive transfer of Tag-specific TCR splenocytes following sub-lethal irradiation results in T cell infiltration
of solid tumors. Representative frozen sections of tumors from 16 week old Rip1-Tag2 pancreas were analyzed by immuno-
histochemistry for CD4, CD8 and CD11c. The transgenic mice were treated as follows: (A-C) untreated, (D-F) TCR spleno-
cytes, (G-I) 600R, and (J-L) 600R + TCR splenocytes. Extensive CD4+ T cell infiltration (A, D, G, J) is observed only in mice
receiving both sub-lethal irradiation and adoptively transferred TCR splenocytes (J). When analyzed for infiltration by CD8+ T
cells (B, E, H, K), again only tumors from mice treated with the combination therapy showed significant infiltration (K). Den-
dritic cells, as detected by the antibody to CD11c (C, F, I, L), were observed in all tumors, but mice receiving both 600R (I) and
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notable that the mice receiving the combination treat-
ment had a mean tumor volume of 4.6 mm3 (p = 0.0004)
and an average tumor number of 2.3, comparable to the
situation at the beginning of the trial. Thus, a condition of
'stable disease' was achieved in the group that received the
combinatorial therapy
In the regression trial, RIP1-Tag2 mice with substantial tu-
mor burden and minimal life expectancy were treated be-
ginning at week 13 [33]. The average tumor volume was
around 22 mm3 at the start of the treatment (Figure 2).
The tumor burden of the untreated control group at the
end of the study was ~146 mm3. No reduction in tumor
burden was observed following adoptive transfer of non-
transgenic splenocytes alone (132% of controls). In con-
trast, sub-lethal radiation alone resulted in a significant re-
duction of tumor burden (63%, p = 0.01). The
combinatorial treatment produced an even greater reduc-
tion in tumor burden (80%, p = 0.0009). The average tu-
mor number in all groups was similar (about 8). As
observed in the intervention trial, tumor burden in the
group receiving the combinatorial treatment had re-
mained virtually unchanged. Thus, even with substantial
tumor burden, the combination of sub-lethal radiation
and splenocyte transfer could stop tumor growth during
the course of the study.
Sub-lethal radiation increases lymphocyte infiltration of 
tumors
Because the combination of sub-lethal radiation and TCR
splenocyte transfer lead to significant reduction in tumor
burden in both intervention and regression trials, we
asked whether the radiation had increased the number of
tumor-infiltrating lymphocytes. Tissue samples were col-
lected three weeks after treatment in the regression trial.
Immunohistochemistry was used to detect CD4+, CD8+
and CD11c+ cell infiltration into the tumors. Because
Rip1-Tag2 mice are inherently tolerant to Tag, little infil-
tration by either T lymphocytes or dendritic cells was ob-
served in the untreated control group (Figure 3). In
agreement with previous observations, little infiltration
was detected in Rip1-Tag2 mice receiving TCR splenocyte
transfer (Figure 3). Nor did radiation alone elicit T cell in-
filtration, although a modest increase in CD11c+ dendritic
cell infiltration was observed. However, in both interven-
tion and regression trials, significant CD4+ T cell and
CD8+ T cell infiltration into hyperplastic/dysplastic islets
and tumors was noted in Rip1-Tag2 mice that had re-
ceived the combination of sub-lethal radiation and adop-
tive transfer of TCR splenocytes. A modest increase in
CD11c+ dendritic cell infiltration was observed in the
mice receiving the combination therapy. One should re-
call that the TCR mice express a CD4-restricted TCR, and
thus produce increased numbers of anti-Tag CD4 T cells,
and thus we anticipated a bias in numbers toward this T
cell type. Indeed, one week after treatment, little CD8+ T
infiltration of premalignant or malignant lesions was de-
tected in Rip1-Tag2 mice receiving the combinatorial
treatment (data not shown). However, three weeks after
combinatorial treatment in the regression trial, significant
CD8+ T cell infiltration was observed in solid tumors, sug-
gesting a broadening of the T cell response from that con-
tained in the adoptive transfer.
Combining adoptive transfer and sub-lethal radiation pro-
longs survival
The trials above used defined endpoints (12.6 week and
16 week) to allow comparison of cumulative tumor vol-
ume and number. To evaluate the effects of the various
treatments on survival, we performed intervention and re-
gression trials on cohorts of Rip1-Tag2 mice, in which
groups received no treatment, radiation alone, or the
combinatorial treatment, in which the endpoint was sur-
vival. Because splenocyte transfer alone had resulted in no
significant reduction in tumor burden, this group was not
tested for survival benefit, for logistical reasons. All Rip1-
Tag2 mice in the study eventually succumbed to their can-
cers. Although radiation treatment alone impaired tumor
growth in both intervention and regression trials, it pro-
duced no significant extension of survival time in either
trial (Figure 4). In contrast, there was a significant exten-
sion of survival of cohorts receiving the combinatorial
treatment in the intervention and regression trials. The ef-
fect was pronounced in the intervention trial, with an ex-
tension of survival of 5 weeks (p < 0.0001, log-rank). In
the regression trial the extension of survival time was
about 3 weeks (p = 0.001, log-rank). No extension of sur-
vival time was observed in mice treated with 600R and
syngeneic C3H splenocytes (p = 0.6893, log-rank). Thus,
the observed reduction of tumor burden produced by the
combinatorial treatment translated into significant surviv-
al advantage, and the effect was dependent on the in-
creased frequency of tumor-antigen specific T cells from
the TCR transgenic.
Because the single combination treatment lead to clear
therapeutic benefits and yet did not eradicate established
tumors, we asked whether mice would benefit from re-
peated treatments. Both intervention and regression trials
were conducted. Rip1-Tag2 mice were given the combina-
tion treatment at 10-weeks and again at 13-weeks of age
for an intervention trial, or at 13 and 16-weeks for a re-
gression trial. Survival was monitored over time. The re-
sults show no added survival benefit when the treatment
regimen was repeated (Figure 4). The mean survival time
was statistically equivalent to that observed in the groups
given a single combinatorial treatment in the intervention
trial, and in the regression trial the cohort given a double
combinatorial treatment showed no significant extensionBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/11
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Figure 4
Combinatorial therapy prolongs survival in RIP1-Tag2 mice. Effect of treatment on survival in (A) 10 week old (inter-
vention) and (B) 13 week old (regression) RIP1-Tag2 mice. Between 10–12 mice were tested in each cohort. In the interven-
tion trial (A), cohorts were treated with: untreated (closed circles, n = 12), 600R (open triangles, n = 10), TCR splenocytes +
600R (closed squares, n = 10) and TCR splenocytes + 600R (x2) (x, n = 10) and allowed to age until they became moribund.
Statistical analysis was done using a log-rank test. P values comparing experimental groups to untreated control mice are
TCR+600R (<0.0001) and TCR+600R(x2) (0.0003). In the regression trial (B), cohorts were treated as above with an addi-
tional control group C3H splenocytes + 600R (closed diamonds, n = 10) and allowed to age until they became moribund. The
sample sizes are: untreated control, n = 12; 600R alone, n = 11; TCR splenocytes + 600R, n= 16; TCR splenocytes + 600R (x2),
n = 9. P values comparing experimental groups to untreated control mice are TCR+600R (0.001) and TCR+600R(x2) (0.0715).BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/11
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of survival time as compared to untreated controls (p =
0.07, log-rank).
Discussion
Previous studies using lethal dose radiation and bone
marrow transplant prior to CD4+ T cell transfer in another
Rip-Tag line of mice indicated that such treatment could
produce a modest increase in the number of tumor-infil-
trating T cells [22]. The current study extends the thesis by
focusing on the use of sub-lethal radiation to enhance the
anti-tumor immunity of adoptively transferred tumor-an-
tigen-specific lymphocytes in Rip1-Tag2 mice. The splen-
ocytes were derived from T cell receptor transgenic mice
that preferentially enhanced development of CD4+ T cells
recognizing a peptide within the SV40 large T oncoprotein
[28]. While the transfer of naive splenocytes from the TCR
transgenic mice had no effect on tumor development,
sub-lethal radiation prior to lymphocyte transfer resulted
in significant reduction in tumor burden in both interven-
tion and regression trials. In addition, Rip1-Tag2 mice re-
ceiving the combinatorial treatment had significantly
longer survival time than those receiving single treatment.
Immunohistochemical analysis indicates that the combi-
natorial treatment dramatically increased the level of infil-
tration by CD4+ lymphocytes and CD11c+ dendritic cells
into solid tumors. Due to the nature of this line of TCR
transgenic mice, only about 10% of splenic CD4+ T cells
are Tag-specific. Thus, it is possible that some of the tu-
mor-infiltrating, CD4+ T cells may recognize targets other
than Tag. This may be the result of the "bystander" effects
induced by the tumor-infiltrating, Tag-specific, CD4+ T
cells. The elucidation of this phenomenon with idiotype-
specific antibodies or tetramers in future experiments
would clarify the extent of "bystander" effects in this mod-
el. Although delayed when compared to CD4+ T cell infil-
tration, CD8+ T cell infiltration became more extensive
over time. We speculate that the tumor-infiltrating, CD4+
T cells would induce the activation and tumor-infiltration
of CD8+ T cells present in the transferred transgenic splen-
ocytes. This pattern, as well as the origin of the spleno-
cytes, suggests that CD4+ T cells can play a predominant
and effective role in controlling tumor growth.
Previous studies have indicated that solid tumors can be
resistant to the infiltration of tumor-specific T cells. The
data presented here suggest that such resistance can be dis-
rupted by sub-lethal radiation. Several possible mecha-
nisms for the enhancing effects of sub-lethal radiation on
anti-tumor immunity can be envisioned, as discussed be-
low. First, sub-lethal radiation may reduce antigen-specif-
ic immune tolerance mediated by bone marrow-derived
cells, including regulatory T cells, in the tumor-draining
lymph nodes. Previous studies have shown that adoptive-
ly transferred tumor antigen-specific CD4+ T cells can be
tolerized in the secondary lymphoid organs [9,34], in-
cluding the RIP-Tag2 model [30]. Radiation may kill or
disable regulatory T cells [35,36], or other bone marrow-
derived tolerizing cells and prevent the induction of toler-
ance in adoptively transferred tumor-specific T cells [9].
Additionally, the high but sub-lethal dose of radiation
used leads to significant lymphopenia [37]. The sudden
reduction in lymphocyte number may create the spatial
allowance in spleen and lymph nodes necessary for the
homing, activation and expansion of he adoptively-trans-
ferred T cells. The increase of tumor-specific CD4+ T cells
in the tumor-draining lymph nodes could then enhance
the infiltration of T cells inside the solid tumors.
Second, radiation-induced damage or abnormality may
induce a "tissue damage signal" in the solid tumors
through radiation-mediated apoptosis [38]. There is
mounting evidence that apoptotic cell death is not immu-
nologically benign, but can trigger immune responses
[39,40]. For example, cells treated with ultraviolet radia-
tion can provide potent adjuvant function in vivo [41].
Sub-lethal radiation could result in altered expression of
pro or anti-inflammatory chemokines [42–44] or in-
creased expression of T cell co-stimlulatory molecules (i.e.
B7-1) on tumor cells [45]. Radiation has been shown to
increase the expression of MHC class I and II molecules in
tumor cell lines [46,47]. Thus, the tissue damage signals
evoked by ionizing radiation may trigger the activation
and infiltration of antigen-presenting cells, in particular
dendritic cells [38,48–50]. Indeed, in the regression study,
we observe some increase of tumor-infiltrating dendritic
cells in the group receiving the single radiation treatment.
It is possible that radiation-induced, tumor-infiltrating
dendritic cells may facilitate sustained activation and infil-
tration of the adoptively transferred CD4+ T cells in solid
tumors in the combination group.
Third, radiation may alter the biophysical structures of tu-
mors, which in some tumors has the capability to impair
the infiltration or function of tumor-specific T cells. For
example, in the related Rip1-Tag5 model, the vascular ad-
dressins GlyCAM-1 and MAdCAM-1 are expressed in pre-
malignant islets, but down-regulated in solid tumors;
their downregulation coincides with lack of infiltration in
this model of spontaneous anti-tumor immunity [19]. It
is possible that sub-lethal radiation is altering the expres-
sion of endothelial adhesion molecules allowing binding
and extravasation of activated tumor-specific lym-
phocytes. Another study suggested that liver endothelial
cells can induce antigen-specific tolerance of CD8+ T cells
[51]. Perhaps RIP-Tag tumor endothelium develops a sim-
ilar capability to induce tolerance to extravasating CD4+ T
cells, a capability disrupted by radiation.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/11
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Finally, it is worth noting that the tumors in Rip1-Tag2
mice are not only highly vascularized, but also visibly and
histologically hemorraghic. The hemorraghic phenotype
persisted in all single agent trials, but the combination tri-
al was distinct. The mice in the combination treatment
group typically had "white" tumors that lacked visible mi-
crohemorrhaging. A recent study has suggested that tu-
mor-specific, CD4+ T cells can exert anti-tumor effects by
inhibiting angiogenesis via release of IFN-γ  [11]. Thus, the
"white" tumors noted in the current study may be indica-
tive of angiogenic inhibition by the infiltrating tumor-spe-
cific, CD4+ T cells, and such inhibition may be relevant to
the observed efficacy. An analysis of the tumor vasculature
in the combination trial by immunohistochemical stain-
ing for the endothelial cell marker CD31 revealed no ob-
vious structural or density changes in tumor blood vessels
(data not shown). Future analysis of molecular markers of
the tumor vasculature during and after the combinatorial
treatment will explore the possibility that more subtle vas-
cular changes are responsible for the observed efficacy.
While the underlying mechanisms remain unknown, it is
evident that a combination of sub-lethal radiation and the
transfer of tumor-specific CD4+ lymphocytes can have a
synergistic effect on tumor regression. While the anti-tu-
mor effect of the combinatorial treatment does not com-
pletely resolve tumor burden and the mice eventually
succumb, it is important to recognize that the Rip1-Tag2
mice are a very stringent system for assaying immuno-
therapies because of the multifocal nature of tumor pro-
gression in these mice. Because the Tag oncogene is
expressed in all of the ~500,000 pancreatic β  cells, each of
~400 islets can be considered an independent pre-malig-
nant focus. Hence, the immunotherapy tested herein
would have to destroy all neoplastic foci to affect a com-
plete cure, which is perhaps too much to expect; our view
is that the stringency of this system has advantages as a re-
adout for therapeutic strategies, in the observed efficacy
may be more predictive of responses in the clinic that
those observed with subcutaneous tumors. We expect that
clarification of the underlying mechanism may provide
avenues to improved therapeutic strategies based on the
concept of disrupting the evident barriers to effective anti-
tumor immunity erected by solid tumors. We suggest that
the combinatorial approach presented here merits consid-





TCR, T cell receptor; MHC, major histocompatibility com-
plex; H-2, murine MHC locus; Tag, SV40 T antigen; RIP,
rat insulin promoter; RAG, recombinase activating gene.
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